Literature DB >> 27189860

Blood group A and D negativity are associated with symptomatic West Nile virus infection.

Zhanna Kaidarova1, Marjorie D Bravo2, Hany T Kamel2, Brian S Custer1,3, Michael P Busch1,3, Marion C Lanteri1,3.   

Abstract

BACKGROUND: West Nile virus (WNV) infection is mostly asymptomatic (AS) but 20% of subjects report WNV fever and 1% of patients experience neurologic diseases with higher rates in elderly and immunosuppressed persons. With no treatment and no vaccine to prevent the development of symptomatic (S) infections, it is essential to understand prognostic factors influencing S disease outcome. Host genetic background has been linked to the development of WNV neuroinvasive disease. This study investigates the association between the ABO and D blood group status and WNV disease outcome. STUDY DESIGN AND METHODS: The distribution of blood groups was investigated within a cohort of 374 WNV+ blood donors including 244 AS and 130 S WNV+ blood donors. Logistic regression analyses were used to examine associations between A, B, O, and D blood groups and WNV clinical disease outcome.
RESULTS: S WNV+ donors exhibited increased frequencies of blood group A (S 47.6%, AS 36.8%, p = 0.04; odds ratio [OR], 1.56; 95% confidence interval [CI], 1.01-2.40) and D- individuals (S 21.5%, AS 13.1%, p = 0.03; OR, 1.82; 95% CI, 1.04-3.18).
CONCLUSION: The findings suggest a genetic susceptibility placing blood group A and D- individuals at risk for the development of S disease outcome after WNV infection.
© 2016 AABB.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27189860      PMCID: PMC4938756          DOI: 10.1111/trf.13622

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  46 in total

1.  ABO blood group and susceptibility to severe acute respiratory syndrome.

Authors:  Yunfeng Cheng; Yufeng Cheng; Gregory Cheng; C H Chui; F Y Lau; Paul K S Chan; Margaret H L Ng; Joseph J Y Sung; Raymond S M Wong
Journal:  JAMA       Date:  2005-03-23       Impact factor: 56.272

Review 2.  Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzle.

Authors:  Ming Tan; Xi Jiang
Journal:  Trends Microbiol       Date:  2005-06       Impact factor: 17.079

3.  Blood group AB is associated with increased risk for severe dengue disease in secondary infections.

Authors:  Siripen Kalayanarooj; Robert V Gibbons; David Vaughn; Sharone Green; Ananda Nisalak; Richard G Jarman; Mammen P Mammen; Guey-Chuen Perng
Journal:  J Infect Dis       Date:  2007-02-23       Impact factor: 5.226

Review 4.  Defining the Rh blood group antigens. Biochemistry and molecular genetics.

Authors:  J P Cartron
Journal:  Blood Rev       Date:  1994-12       Impact factor: 8.250

5.  Relative distribution of West Nile virus RNA in blood compartments: implications for blood donor nucleic acid amplification technology screening.

Authors:  Lori Lai; Tzong-Hae Lee; Leslie Tobler; Li Wen; Ping Shi; Jeff Alexander; Helen Ewing; Michael Busch
Journal:  Transfusion       Date:  2011-08-09       Impact factor: 3.157

Review 6.  West Nile virus infection and immunity.

Authors:  Mehul S Suthar; Michael S Diamond; Michael Gale
Journal:  Nat Rev Microbiol       Date:  2013-02       Impact factor: 60.633

7.  Associations between West Nile virus infection and symptoms reported by blood donors identified through nucleic acid test screening.

Authors:  Brian Custer; Hany Kamel; Nancy E Kiely; Edward L Murphy; Michael P Busch
Journal:  Transfusion       Date:  2009-02       Impact factor: 3.157

Review 8.  The ABO blood group system and Plasmodium falciparum malaria.

Authors:  Christine M Cserti; Walter H Dzik
Journal:  Blood       Date:  2007-05-14       Impact factor: 22.113

9.  Risk factors for West Nile virus neuroinvasive disease, California, 2005.

Authors:  Cynthia M Jean; Somayeh Honarmand; Janice K Louie; Carol A Glaser
Journal:  Emerg Infect Dis       Date:  2007-12       Impact factor: 6.883

10.  Increased frequency of Tim-3 expressing T cells is associated with symptomatic West Nile virus infection.

Authors:  Marion C Lanteri; Michael S Diamond; Jacqueline P Law; Glen M Chew; Shiquan Wu; Heather C Inglis; Derek Wong; Michael P Busch; Philip J Norris; Lishomwa C Ndhlovu
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

View more
  5 in total

Review 1.  ABO blood group and COVID-19: an updated systematic literature review and meta-analysis.

Authors:  Massimo Franchini; Mario Cruciani; Carlo Mengoli; Giuseppe Marano; Fabio Candura; Nadia Lopez; Ilaria Pati; Simonetta Pupella; Vincenzo De Angelis
Journal:  Blood Transfus       Date:  2021-05-12       Impact factor: 3.443

2.  Association of blood groups on the risk of COVID-19 infection, morbidity, and mortality.

Authors:  Meltem Sertbas; Volkan Kizilay; Selma Dagci; Pinar Eker; Zeynep Yazici; Ebru Elci Solak; Serkan Elarslan; Nurettin Yiyit; Yasar Sertbas; Kamil Ozdil
Journal:  North Clin Istanb       Date:  2021-05-26

3.  The role of host genetics in susceptibility to severe viral infections in humans and insights into host genetics of severe COVID-19: A systematic review.

Authors:  Abdelazeem Elhabyan; Saja Elyaacoub; Ehab Sanad; Abdelwahab Abukhadra; Asmaa Elhabyan; Valentin Dinu
Journal:  Virus Res       Date:  2020-09-09       Impact factor: 3.303

4.  Emphasizing the link between blood types in multi-ethnic disparities and COVID-19 infection in Makkah, Saudi Arabia.

Authors:  Wesam A Nasif; Abeer S E Ali; Asim A Khogeer; Mohammed H Mukhtar; Mohamed M NourEldein; Ahmed Y Shebly; Shmukh H Alqahtani; Yahya A Alnashri; Ghidaa E Khouj; Ziyad I Gadah; Mohammad A Althubiti
Journal:  Saudi Med J       Date:  2022-02       Impact factor: 1.422

5.  Seroprevalence of hepatitis E virus among blood donors on Corsica, France, 2017.

Authors:  Lisandru Capai; Nathanaël Hozé; Jacques Chiaroni; Sylvie Gross; Rachid Djoudi; Rémi Charrel; Jacques Izopet; Frédéric Bosseur; Stéphane Priet; Simon Cauchemez; Xavier de Lamballerie; Alessandra Falchi; Pierre Gallian
Journal:  Euro Surveill       Date:  2020-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.